Jaguar Health, Inc.

As of August 9, 2017, Jaguar Health, Inc. is considered overvalued and risky due to its poor financial metrics, including a Price to Book Value of 1.20, an EV to Sales ratio of 3.18, a ROE of -742.25%, and a year-to-date stock performance decline of -89.31%, especially when compared to its peers.

As of June 11, 2025, the technical trend has shifted to mildly bearish due to daily moving averages and other indicators signaling weakness in bullish momentum, despite some mixed signals from the weekly MACD and KST.

As of March 2022, the management team of Jaguar Health, Inc. includes CEO Lisa Conte, Independent Chairman James Bochnowski, and several Independent Directors: Gregory Divis, John Micek, Jiahao Qiu, and Jonathan Siegel.

Jaguar Health, Inc. is a micro-cap pharmaceuticals company focused on developing sustainable gastrointestinal products for humans and animals. As of March 2025, it reported net sales of $2 million and a net loss of $11 million, with a market cap of $4.09 million.

As of Jun 18, Jaguar Health, Inc. has a market capitalization of 4.09 million, with net sales of 11.55 million and a net profit of -40.48 million over the latest four quarters. Shareholder's funds are at 9.77 million, and total assets amount to 53.42 million.